Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,591 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bones Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

NCT00813228
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Interventions
Sitagliptin (Januvia)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 31, 2026, 12:23 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) Interpretations for Lumbar Spinal Stenosis (LSS)

NCT01017692
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
MRI
Procedure
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

NCT00301834
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions
alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 31, 2026, 12:23 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy

NCT07896928
View directory record Official record
Conditions
MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome
Interventions
Allogeneic Stem Cell Transplant
Procedure
Lead sponsor
Ronald Paquette
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

NCT00003336
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, melphalan, methylprednisolone, bone marrow ablation with stem cell support, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

NCT01272830
View directory record Official record
Conditions
Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions
Placebo, Apatone®B
Drug
Lead sponsor
IC-MedTech Corporation
Industry
Eligibility
50 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

NCT01290367
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Single Dose MPCs Injection, Single injection of saline solution, Single injection of hyaluronic acid
Biological · Procedure
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

NCT00030667
View directory record Official record
Conditions
Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma, Gastrointestinal Stromal Tumor, Lung Metastases, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis

NCT02260401
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Individualized report
Other
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 31, 2026, 12:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

NCT03722407
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 12:23 PM EDT
Withdrawn Phase 2 Interventional

The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa

NCT00853502
View directory record Official record
Conditions
Bone Metabolism
Interventions
testosterone cypionate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 30 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 31, 2026, 12:23 PM EDT
Completed No phase listed Observational

Validation of Appropriateness Criteria for the Surgical Treatment of Lumbar Degenerative Spondylolisthesis

NCT02966639
View directory record Official record
Conditions
Spondylolisthesis
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 31, 2026, 12:23 PM EDT
Not yet recruiting Phase 2 Interventional

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

NCT07634536
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
Interventions
VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide, Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT), Mycophenolate mofetil (MMF), Tacrolimus
Radiation · Drug · Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 12:23 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional Results available

AMG 827 in Subjects With Psoriatic Arthritis

NCT01516957
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AMG 827 140, Placebo, AMG 827 280, AMG 827 210
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 31, 2026, 12:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

NCT03851081
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

NCT02048371
View directory record Official record
Conditions
Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
Interventions
Regorafenib, Placebo
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
5 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Not applicable Interventional

e-OPRA Implant System for Lower Limb Amputees

NCT03720171
View directory record Official record
Conditions
Amputation
Interventions
e-OPRA Implant System
Device
Lead sponsor
Integrum
Industry
Eligibility
22 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures?

NCT02216812
View directory record Official record
Conditions
Finger Stiffness, Distal Radius Fracture
Interventions
500 mg vitamin c, 1 pill per day for 6 weeks, 1 placebo pill for 6 weeks
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 31, 2026, 12:23 PM EDT
Terminated Phase 1 Interventional Results available

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

NCT02848001
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-90009
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Stanford, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 31, 2026, 12:23 PM EDT
Not listed Not applicable Interventional

Bio-Integrative Versus Metallic Screws for Calcaneus Osteotomies

NCT05018130
View directory record Official record
Conditions
Flatfoot, Bone Resorption, Cavus Deformity, Osteolysis, Complication
Interventions
Calcaneus Osteotomy (Metallic), Calcaneus Osteotomy (Bio-integrative)
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 31, 2026, 12:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy Adults

NCT07453537
View directory record Official record
Conditions
Stress Response, Mental Stress, Multitasking Behavior and Multitasking Ability, Physiological Stress, Cognitive Symptoms, Motor Activity
Interventions
Cranberry juice, Placebo juice
Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 12:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

NCT00578981
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
Interventions
Osteoporosis Choice Decision Aid
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 31, 2026, 12:23 PM EDT
Not listed No phase listed Observational

Idys™ TLIF 3DTi Post Market Clinical Follow-up

NCT04584619
View directory record Official record
Conditions
Degenerative Disc Disease, Grade 1 Spondylolisthesis
Interventions
Spine fusion surgery with Clariance Idys TLIF 3DTi
Device
Lead sponsor
Clariance
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 31, 2026, 12:23 PM EDT